Skip to main content

Advertisement

Table 3 FOIAS of phases 1–3 and PVM (PrimaVistaMode) in FOI at baseline and after 12 months (n = 35 for FOIAS parameters

From: Fluorescence optical imaging for treatment monitoring in patients with early and active rheumatoid arthritis in a 1-year follow-up period

  Month of visit 0 (V0)* Month of visit 12 (V12)* Difference between V12 and V0* p value (Wilcoxon signed rank test)
Phase 1 5 (1.04;26) (0;70.91) 1 (0;4) (0;32) −3 (− 17;0) (−69.91;12) 0.00445 (sig.)
Phase 2 16 (10.5;25) (1;40) 16 (9.5;24) (2;43) 2 (−4.5;6.81) (− 18;18) 0.6004
Phase 3 1 (0;2.5) (0;15) 1 (0;4) (0;10) 0 (− 1;1.5) (− 12;9) 0.5451
PVM 9 (4.5;13) (0;24) 9 (3.5;14) (0;26) −1 (−4;4) (− 15;14) 0.7461
  1. Phases 1–3 and PVM (PrimaVistaMode) of FOI at baseline and after 12 months (n = 35): FOIAS fluorescence optical imaging activity score; *median (1. quartile; 3. quartile); (min; max); significance level = 0.05